South Korea plans to conduct a re-evaluation of reimbursed drugs with a view to cutting their prices or delisting them from the national health insurance tariff if they fail to meet certain conditions, and also to lower prices of generics through regular comparisons with overseas prices.
Both moves are being mulled in an attempt to cut rising expenditure under the universal care system.








